Literature DB >> 21519800

P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.

Ragini Gupta1, Yogendra Prasad.   

Abstract

Staphylococcus aureus causes a wide range of suppurative infections in humans and animals. Due to its high virulence, ability to adopt various environmental conditions, and acquired multiple drug resistance, treatment of such infections has become difficult. Therefore, there is an immense need to develop alternate drug modalities to control this pathogen. In past few years, phage-encoded endolysin therapy has emerged as a new hope not only due to its ability to specifically kill the target bacteria irrespective of their antibiotic sensitivity but also because of minimum or no side effects, a problem associated with antibiotic therapy. In this article, we report purification of a broad spectrum anti-staphylococcal endolysin (P-27/HP endolysin) encoded by phage P-27/HP isolated from sewage water. On SDS-PAGE endolysin resolved in three polypeptides of molecular weights 33.5, 48.6, and 62.2 kDa. Endolysin exhibited maximum in vitro lytic activity at temperature between 35 and 40°C and pH 7.0. In vivo experiments revealed considerable (99.9%) elimination of S. aureus 27/HP from spleens of endolysin-treated mice and had saved them from death due to bacteremia caused by S. aureus 27/HP challenge infection. Thus, P-27/HP endolysin offers suitable substitute of antibiotics to control S. aureus infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519800     DOI: 10.1007/s00284-011-9939-8

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  24 in total

1.  Community-associated MRSA--resistance and virulence converge.

Authors:  Henry F Chambers
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

Review 2.  Bacteriophage endolysins--current state of research and applications.

Authors:  Martin J Loessner
Journal:  Curr Opin Microbiol       Date:  2005-08       Impact factor: 7.934

Review 3.  Phage therapy in clinical practice: treatment of human infections.

Authors:  Elizabeth Kutter; Daniel De Vos; Guram Gvasalia; Zemphira Alavidze; Lasha Gogokhia; Sarah Kuhl; Stephen T Abedon
Journal:  Curr Pharm Biotechnol       Date:  2010-01       Impact factor: 2.837

4.  Staphylococcal bacteriophage-associated lysin: a lytic agent active against Staphylococcus aureus.

Authors:  S A Sonstein; J M Hammel; A Bondi
Journal:  J Bacteriol       Date:  1971-08       Impact factor: 3.490

Review 5.  Bacteriophage endolysins as a novel class of antibacterial agents.

Authors:  Jan Borysowski; Beata Weber-Dabrowska; Andrzej Górski
Journal:  Exp Biol Med (Maywood)       Date:  2006-04

6.  Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus.

Authors:  Marian Takác; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11.

Authors:  Shigenobu Matsuzaki; Masaharu Yasuda; Hiroshi Nishikawa; Masayuki Kuroda; Takako Ujihara; Taro Shuin; Yuan Shen; Zhe Jin; Shigeyoshi Fujimoto; M D Nasimuzzaman; Hiroshi Wakiguchi; Shigeyoshi Sugihara; Tetsuro Sugiura; Shigeki Koda; Asako Muraoka; Shosuke Imai
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

Review 8.  Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides.

Authors:  A Parisien; B Allain; J Zhang; R Mandeville; C Q Lan
Journal:  J Appl Microbiol       Date:  2008-01       Impact factor: 3.772

9.  Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus.

Authors:  Salim Manoharadas; Angela Witte; Udo Bläsi
Journal:  J Biotechnol       Date:  2008-09-26       Impact factor: 3.307

10.  Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.

Authors:  Martin Witzenrath; Bernd Schmeck; Jan M Doehn; Thomas Tschernig; Janine Zahlten; Jutta M Loeffler; Maren Zemlin; Holger Müller; Birgitt Gutbier; Hartwig Schütte; Stefan Hippenstiel; Vincent A Fischetti; Norbert Suttorp; Simone Rosseau
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

View more
  19 in total

1.  Intrinsic resistance of Enterococcus faecalis strains to ΦEf11 phage endolysin is associated with the presence of ΦEf11 prophage.

Authors:  Hongming Zhang; Roy H Stevens
Journal:  Arch Virol       Date:  2020-11-09       Impact factor: 2.574

2.  Bacteriophage φEf11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins.

Authors:  Hongming Zhang; Roy H Stevens; Bettina A Buttaro; Derrick E Fouts; Salar Sanjari; Bradley S Evans
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

Review 3.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 4.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

5.  Characterization of LysB4, an endolysin from the Bacillus cereus-infecting bacteriophage B4.

Authors:  Bokyung Son; Jiae Yun; Jeong-A Lim; Hakdong Shin; Sunggi Heu; Sangryeol Ryu
Journal:  BMC Microbiol       Date:  2012-03-15       Impact factor: 3.605

Review 6.  Bacteriophages and phage-derived proteins--application approaches.

Authors:  Zuzanna Drulis-Kawa; Grazyna Majkowska-Skrobek; Barbara Maciejewska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 7.  Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus.

Authors:  Piotr Szweda; Marta Schielmann; Roman Kotlowski; Grzegorz Gorczyca; Magdalena Zalewska; Slawomir Milewski
Journal:  Appl Microbiol Biotechnol       Date:  2012-10-18       Impact factor: 4.813

8.  Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis.

Authors:  Yihui Yuan; Qin Peng; Meiying Gao
Journal:  BMC Microbiol       Date:  2012-12-19       Impact factor: 3.605

Review 9.  Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.

Authors:  Zuzanna Drulis-Kawa; Grazyna Majkowska-Skrobek; Barbara Maciejewska; Anne-Sophie Delattre; Rob Lavigne
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

10.  Expression and delivery of an endolysin to combat Clostridium perfringens.

Authors:  Teresa Gervasi; Nikki Horn; Udo Wegmann; Giacomo Dugo; Arjan Narbad; Melinda J Mayer
Journal:  Appl Microbiol Biotechnol       Date:  2013-08-15       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.